Tgf Beta Signaling Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Transforming Growth Factor-beta (TGF-β) signaling pathway is a highly conserved cellular communication system that plays dual roles in the nervous system—promoting neuronal survival under normal conditions while contributing to disease progression when dysregulated. TGF-β signaling regulates neuroinflammation, neurogenesis, synaptic plasticity, and oligodendrocyte function, making it a critical pathway in neurodegenerative disease pathogenesis[1][2].
flowchart TD
subgraph Ligands
TGFB1[TGF-β1] -->
TGFB2[TGF-β2] -->
TGFB3[TGF-β3] -->
BMP2[BMP-2] -->
BMP4[BMP-4] -->
GDF5[GDF-5]
end
subgraph Receptors
TBR2[TβRII] -->
TBR1[TβRI] -->
BMPR2[BMPRII] -->
BMPR1[BMPRI] -->
ALK1[ALK1/Endoglin]
end
subgraph SMAD Pathway
SMAD23[SMAD2/3] -->
SMAD4[SMAD4] -->
SMAD67[SMAD6/7] -->
P_SMAD23[p-SMAD2/3]
end
subgraph Non-SMAD Pathways
MAPK[MAPK/ERK] -->
PI3K[PI3K/Akt] -->
JNK[JNK/p38]
end
subgraph Outcomes
INFLAM[Neuroinflammation)
NEURO[Neurogenesis)
SYNAP[Synaptic Plasticity)
MYEL[Oligodendrocyte] -->
APOP[Apoptosis)
end
TGFB1 --> TBR2
TGFB2 --> TBR2
TGFB3 --> TBR2
BMP2 --> BMPR2
BMP4 --> BMPR2
TBR2 --> TBR1
BMPR2 --> BMPR1
TBR1 --> P_SMAD23
BMPR1 --> P_SMAD23
ALK1 --> P_SMAD23
P_SMAD23 --> SMAD4
SMAD4 --> NEURO
SMAD4 --> SYNAP
SMAD4 --> INFLAM
SMAD4 --> APOP
P_SMAD23 --> SMAD67
SMAD67 -.->|Inhibition| TBR1
TBR1 --> MAPK
TBR1 --> PI3K
TBR1 --> JNK
MAPK --> NEURO
MAPK --> SYNAP
PI3K --> NEURO
PI3K --> APOP
JNK --> INFLAM
NEURO --> MYEL
| Component |
Symbol |
Function |
| TGF-β1 |
TGFB1 |
Pro-inflammatory cytokine, key in neuroinflammation |
| TGF-β2 |
TGFB2 |
Oligodendrocyte differentiation, myelination |
| TGF-β3 |
TGFB3 |
Neuronal survival, synaptic plasticity |
| TGF-β Receptor I |
TGFBR1 |
Serine/threonine kinase, primary signal transducer |
| TGF-β Receptor II |
TGFBR2 |
Constitutively active kinase, ligand binding |
| SMAD2 |
SMAD2 |
R-SMAD, TGF-β canonical pathway |
| SMAD3 |
SMAD3 |
R-SMAD, transcription co-activator |
| SMAD4 |
SMAD4 |
Co-SMAD, forms complexes with R-SMADs |
| SMAD6/7 |
SMAD6/7 |
I-SMAD, inhibitory SMADs |
| SARA |
SMAD anchor for receptor activation |
Facilitates SMAD2/3 recruitment |
The TGF-β superfamily bifurcates into two major subpathways:
- TGF-β/Activin pathway: TGFB1-3 → TβRI/TβRII → SMAD2/3 → SMAD4 → transcriptional outcomes
- BMP/GDF pathway: BMPs/GDFs → BMPRI/BMPRII → SMAD1/5/8 → SMAD4 → transcriptional outcomes
This distinction is therapeutically important as BMP signaling promotes neurogenesis while TGF-β signaling can be pro-inflammatory.
TGF-β signaling exhibits complex, stage-dependent effects in AD:
- Early stages: Neuroprotective via SMAD signaling, promoting Aβ clearance through enhanced microglial phagocytosis[3]
- Late stages: Elevated TGF-β1 in AD brains correlates with disease severity; Aβ directly impairs TGF-β signaling by disrupting SMAD nuclear translocation
- Neuro>[4]</supinflammation: TGF-β modulates microglial phenotype—from pro-inflammatory M1 to anti-inflammatory M2—but this balance is disrupted in AD
- Synaptic dysfunction: TGF-β signaling regulates AMPA receptor trafficking and synaptic plasticity; Aβ-induced synaptic loss involves TGF-β pathway dysregulation
Key publications:
- Tesseur et al. (2006) Nature Neuroscience—TGF-β deficiency accelerates Aβ pathology[5]
- Wyss-Coray et al. (2000) Nature—TGF-β1 overexpression reduces Aβ plaques in mice[6]
TGF-β signaling intersects with multiple PD-relevant pathways:
- Dopaminergic neuron survival: TGF-β1 and TGF-β3 promote survival of dopaminergic neurons through PI3K/Akt signaling[7]
- α-Synuclein aggregation: TGF-β signaling can either promote or inhibit α-syn aggregation depending on context; SMAD signaling intersects with LRRK2 pathways
- Neuroinflammation: TGF-β modulates microglial activation; PD-associated LRRK2 mutations affect TGF-β responses
- Levodopa-induced dyskinesia: TGF-β1 expression is elevated in dyskinetic PD patients
Key publications:
- Sortwell et al. (2000) Experimental Neurology—TGF-β1 protects dopaminergic neurons[8]
- Chao et al. (2009) Glia—TGF-β in PD neuroinflammation[9]
TGF-β dysregulation contributes to motor neuron pathology:
- Elevated TGF-β1 in ALS patient CSF and spinal cord tissue[10]
- TDP-43 pathology intersects with SMAD signaling—TDP-43 inclusions sequester SMAD proteins
- Astroglial TGF-β signaling drives non-cell autonomous motor neuron death
- BMP signaling promotes astrocyte differentiation; impaired BMP/TGF-β balance in ALS
Key publications:
- Endo et al. (2015) Nature Communications—TGF-β in ALS pathogenesis[11]
- Phatnani et al. (2013) Nature Genetics—SMAD dysfunction in ALS[12]
- TGF-β1 polymorphisms associated with MSA susceptibility
- Oligodendrocyte dysfunction involves TGF-β pathway impairment
- Neuroinflammation driven by microglial TGF-β signaling
- Mutant huntingtin disrupts TGF-β signaling at multiple levels
- Impaired SMAD transcriptional activity in HD models
- TGF-β modulates BDNF expression—dysregulation affects neuronal survival
Beyond canonical SMAD signaling, TGF-β activates:
- TβRI activates RAS/RAF/MEK/ERK cascade
- Regulates neuronal differentiation, survival
- Cross-talk with neurotrophic factor signaling
- Promotes neuronal survival
- Counteracts apoptosis
- Intersects with insulin/IGF signaling (relevant to AD)
- Pro-inflammatory signaling
- Stress-activated, induces apoptosis
- Activated in neurodegeneration
| Agent | Mechanism | Status | Disease |
|-------|--------|---------|
| Rec---|--------ombinant TGF-β1 | Direct neurotrophic factor | Preclinical | PD, HD |
| BMP-7 (Osteogenic Protein-1) | BMP pathway activation | Phase II (withdrawn) | PD |
| TGF-β gene therapy | AAV-mediated delivery | Preclinical | AD |
| Agent |
Mechanism |
Status |
Disease |
| SB-431542 |
TβRI kinase inhibitor |
Preclinical |
ALS |
| SD-208 |
TβRI kinase inhibitor |
Preclinical |
ALS, PD |
| LY2109761 |
TβRI/II dual inhibitor |
Preclinical |
ALS |
| Fresolimumab |
Anti-TGF-β1 antibody |
Phase I/II |
IPF, oncology |
- SMAD7 gene therapy: Restore inhibitory signaling
- SMAD4 modulators: Enhance canonical signaling
- BET inhibitors: Modulate SMAD-dependent transcription
- Losartan: AT1R antagonist, affects TGF-β cross-talk
- Pirfenidone: Anti-fibrotic, modulates TGF-β
- Minocycline: Inhibits TGF-β expression
| Biomarker |
Source |
Disease |
Utility |
| TGF-β1 |
CSF, serum |
AD, PD, ALS |
Disease progression |
| p-SMAD2/3 |
CSF |
AD |
Diagnostic |
| SMAD7 |
Blood |
ALS |
Progression marker |
| TGFBR2 expression |
Blood cells |
PD |
Susceptibility |
- TGF-β is both upstream and downstream of NF-κB signaling
- Regulates cytokine production (IL-1β, IL-6, TNF-α)
- Modulates microglial activation states
- Cross-talk with BDNF/TrkB signaling
- PI3K/Akt as shared intermediate
- Synergistic neuroprotective effects
- Autophagy regulation via SMAD signaling
- Intersection with mTOR pathway
- Proteostasis modulation
-拮抗关系 in neurogenesis
- Shared transcriptional co-activators
- Therapeutic implications
The TGF-β signaling pathway represents a critical nexus in neurodegenerative disease pathogenesis, with dual roles in neuronal survival and neuroinflammation. While TGF-β agonism shows promise for promoting neuronal survival and Aβ clearance, chronic elevation contributes to pathology. Therapeutic modulation requires careful targeting—ideally restoring physiological signaling rather than complete blockade. The growing understanding of SMAD and non-SMAD pathway interactions, combined with biomarker development, positions TGF-β signaling as an increasingly tractable therapeutic target.
The study of Tgf Beta Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Krieglstein K, et al. (2012) TGF-β in neurodegeneration. Exp Neurol. PMID:22155349
- Tesseur I, Wyss-Coray T (2006) A role for TGF-β in Alzheimer's disease? Nat Med. PMID:16736028
- Wyss-Coray T, et al. (2001) TGF-β1 improves Aβ clearance. Nat Med. PMID:11231578
- Ueberham U, Ueberham E (2020) TGF-β in Alzheimer's disease. J Neural Transm. PMID:32091847
- Tesseur I, et al. (2006) Deficiency in neuronal TGF-beta signaling. Nat Neurosci. PMID:17159942
- Wyss-Coray T, et al. (2000) TGF-β1 reduces amyloid plaques. Nature. PMID:10717490
- Krieglstein K, et al. (1995) TGF-β protects dopaminergic neurons. J Neurosci. PMID:7611521
- Sortwell CE, et al. (2000) TGF-β1 protects dopaminergic neurons. Exp Neurol. PMID:10817915
- Chao CC, et al. (2009) TGF-β in Parkinson's disease. Glia. PMID:19301341
- Endo R, et al. (2015) TGF-β in ALS. Nat Commun. PMID:26522447
- Phatnani HP, et al. (2013) ALS SMART. Nat Genet. PMID:23525077
- Van Hoecke A, et al. (2012) EPHA4 in ALS. Nat Med. PMID:22751994
- Blurton-Jones M, et al. (2009) Neural stem cells and TGF-β. Stem Cells. PMID:19543751
- Yousef H, et al. (2019) TGF-β and aging. Nature. PMID:31168087
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
14 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 36%